Molecular interaction analysis of Sulawesi propolis compounds with SARS-CoV-2 main protease as preliminary study for COVID-19 drug discovery

• Main Authors: Muhamad Sahlan, Rafidha Irdiani, Darin Flamandita, Reza Aditama, Saleh Alfarraj, Mohammad Javed Ansari, Apriliana Cahya Khayrani, Diah Kartika Pratami, Kenny Lischer
• Format: Article
• Language: English
• Published: Elsevier 2021-01-01
• Series: Journal of King Saud University: Science
• Subjects: COVID-19; Molecular docking; Potent inhibitor; SARS-CoV-2 main protease; Sulawesi propolis
• Online Access: http://www.sciencedirect.com/science/article/pii/S1018364720303487

Coronavirus disease 2019 (COVID-19), a respiratory disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a global health concern, as the World Health Organization declared this outbreak to be a global pandemic in March 2020. The need for an effective treatment is urgent because the development of an effective vaccine may take years given the complexity of the virus and its rapid mutation. One promising treatment target for COVID-19 is SARS-CoV-2 main protease. Thus, this study was aimed to examine whether Sulawesi propolis compounds produced by Tetragonula sapiens inhibit the enzymatic activity of SARS-CoV-2 main protease. In this study, molecular docking was performed to analyze the interaction profiles of propolis compounds with SARS-CoV-2 main protease. The results illustrated that two compounds, namely glyasperin A and broussoflavonol F, are potential drug candidates for COVID-19 based on their binding affinity of −7.8 kcal/mol and their ability to interact with His41 and Cys145 as catalytic sites. Both compounds also displayed favorable interaction profiles with SARS-CoV-2 main protease with binding similarities compared to inhibitor 13b as positive control 63% and 75% respectively.